The Vanguard Group 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 4:09 pm Sale | 2026-03-13 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | The Vanguard Group | 0 0.000% | -20,730,939 (Position Closed) | Filing |
| 2024-11-07 10:52 am Purchase | 2024-10-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | The Vanguard Group | 20,730,939 10.020% | 424,343 (+2.09%) | Filing |
| 2024-11-07 10:25 am Unchanged | 2024-09-30 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | The Vanguard Group | 20,306,596 9.810% | 0 (Unchanged) | Filing |
| 2024-11-04 11:18 am Purchase | 2024-09-30 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | The Vanguard Group | 20,306,596 9.810% | 2,542,876 (+14.31%) | Filing |
| 2024-02-13 5:00 pm Purchase | 2023-12-29 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | The Vanguard Group | 17,763,720 8.670% | 3,559,325 (+25.06%) | Filing |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | The Vanguard Group | 14,204,395 7.620% | 4,791,490 (+50.90%) | Filing |
| 2022-02-09 3:33 pm Sale | 2021-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | The Vanguard Group | 9,412,905 5.230% | -2,186,429 (-18.85%) | Filing |